Ann: Annual General Meeting Chairmans Address, page-7

I like the way it radiates confidence throughout:

"The statistic that the Company continues to focus on is that there have been no new products approved to treat acne in more than 20 years – that (amongst others) is a statistic we plan to disrupt with our BTX 1503 program."

[...among others..(?)....and....]

"When Matt and Michael Thurn first started attending dermatology conferences 24 months ago – companies looked at them strangely when they mentioned Botanix was studying synthetic cannabidiol for the treatment of serious skin diseases. In the last 24 months, that attitude has changed as the interest in cannabinoid therapies across a range of diseases has exploded, and significant capital has poured into the sector in pursuit of new opportunities in medicine, general health and recreational usage of cannabinoids."

Something more to look forward in 2019.